RAPT Therapeutics Inc

RAPT Therapeutics — Technical Presentation (June 2021)

15 slides from RAPT Therapeutics's technical presentation, Jun 14, 2021

  1. Slide 1: RPT193 Topline Results

    Transforming the Treatment of Cancer and Inflammation RPT193 Topline Results June 14, 2021 Exhbit 99.2

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the "Company," "we," or "us") research and clinical development pl

  3. Slide 3: Summary

    Summary Topline data from a placebo-controlled double-blinded Phase 1b trial examining 400 mg oral RPT193 as monotherapy for 4 weeks in 31 patients with moderate-to-severe atopic dermatitis* Efficacy: RPT193 demonstrates clear improvement over placebo on all key exploratory endpoints At Day 29: EASI

  4. Slide 4: Atopic Dermatitis Represents a Major Market Opportunity

    Atopic Dermatitis Represents a Major Market Opportunity Atopic dermatitis (AD) is a common disease affecting ~19M adults and ~10M children in the US $24B market by 2029* While the injectable Dupixent® (dupilumab) provides an important option, a well-tolerated, effective, oral drug that does not requ

  5. Slide 5: RPT193 Acts on a Validated Upstream Pathway in Atopic Dermatitis and Asthma

    RPT193 Acts on a Validated Upstream Pathway in Atopic Dermatitis and Asthma Epithelial Barrier Surface CCR4 Th2 CCL17 CCL22 anti-IL4Rα Ab anti-IL5/R Ab anti-IL13 Ab IL-5 IL-4 IL-13 Inflammation Thickening Itch/Cough RPT193 Inhibits Th2 migration and function Cytokines Allergen, Microbes CCR4 regulat

  6. Slide 6: Phase 1b Trial Explores RPT193 Activity in Patients with Moderate-to-Severe Atopic Dermatitis

    Enrolled 31 patients into a double-blind, randomized trial with 2:1 allocation of RPT193 to placebo Monotherapy study: steroid and immunosuppressant washout period; rescue steroids not permitted through Day 43 Trial was not powered for any specific endpoint Exploratory endpoints include: EASI, Pruri

  7. Slide 7: Phase 1b Baseline Demographics

    Phase 1b Baseline Demographics Placebo RPT193 N 10 21 Age, Mean (Range) 35.8 (22-64) 41.0 (19-63) Female, n (%) 4 (40.0%) 12 (57.1%) Baseline Characteristics EASI, Mean (Range) 21.07 (13.6-45.5) 18.49 (12-30) BSA, Mean (Range) 24.5 (10-61) 23.3 (11-55) vIGA 3, n (%) 8 (80.0%) 18 (85.7%) Peak NRS, Me

  8. Slide 8: RPT193 Differentiated from Placebo for EASI and EASI-50 at Day 29

    RPT193 Differentiated from Placebo for EASI and EASI-50 at Day 29 with Further Improvement at Day 43 % Improvement in EASI Proportion of EASI-50 19.3% 43.6% 32.9% 41.9% Follow-up Treatment Follow-up Treatment *p < 0.05 * *

  9. Slide 9: RPT193 Differentiated from Placebo for vIGA Clear/Almost Clear at Day 29

    RPT193 Differentiated from Placebo for vIGA Clear/Almost Clear at Day 29 with Further Differentiation at Day 43 0.0% 0.0% 4.8% 14.3% Proportion of vIGA 0/1 (Clear/Almost Clear)

  10. Slide 10: RPT193 Demonstrates Clinically Meaningful Improvement in Itch Compared to Placebo

    RPT193 Demonstrates Clinically Meaningful Improvement in Itch Compared to Placebo at Day 29 Proportion of NRS-4* 22.2% 45.0% *At least a 4-point improvement among patients with a baseline pruritis NRS ≥4

  11. Slide 11: Safety

    Safety No SAEs reported All AEs reported were mild or moderate in intensity No clinically significant safety laboratory abnormalities observed Overall safety profile to date suggests a well-tolerated oral drug that should not require laboratory safety monitoring

  12. Slide 12: RPT193 6-Week Efficacy Compared to Other Drugs at 12-16 Weeks

    RPT193 6-Week Efficacy Compared to Other Drugs at 12-16 Weeks* RPT193 RPT193 400 mg Biologics Orals Dupilumab Ph3 (300 mg q2wk) Lebrikizumab Ph2 (250 mg q2wk) Tralokinumab Ph3 (300 mg q2wk) Abrocitinib Ph3 (200 mg) Baricitinib Ph3 (2 mg) Etrasimod Ph2 (2 mg) Upadicitinib Ph2,3 (15 mg) % EASI improve

  13. Slide 13: Next Steps for RPT193 Program

    Next Steps for RPT193 Program RPT193 Phase 2 Trials Phase 1b Atopic Dermatitis Phase 2b Atopic Dermatitis Phase 2a Asthma PoC Achieved Adults with moderate-to-severe AD 16-week dosing period Multiple doses RPT193 vs. placebo Goal: Evaluate efficacy and safety at 16 weeks and determine optimal dose f

  14. Slide 14: Conclusion

    Conclusion Data from this Phase 1b study in patients with atopic dermatitis demonstrate clear benefit in key exploratory clinical endpoints including EASI and vIGA Continued deepening of responses through the 2-week follow-up period suggests higher levels of efficacy could be achieved in longer stud

  15. Slide 15: Thank You

    Thank You

RAPT Therapeutics — Technical Presentation (June 2021) on 6ix